Journal of Internal Medicine Concepts & Practice >
Obexelimab for IgG4-related disease: new evidence for non-depleting B-cell inhibition and implications for China
Received date: 2026-07-19
Revised date: 2026-07-22
Accepted date: 2026-07-24
Online published: 2026-08-19
Copyright
LIU Yaoyang . Obexelimab for IgG4-related disease: new evidence for non-depleting B-cell inhibition and implications for China[J]. Journal of Internal Medicine Concepts & Practice, 2026 , 21(03) : 250 -251 . DOI: 10.16138/j.1673-6087.2026.03.09
| [1] | Della-Torre E, Baker MC, Zhang W, et al. Obexelimab for the treatment of IgG4-related disease[J/OL]. N Engl J Med (2026-06-02)[2026-07-19]. https://www.nejm.org/doi/full/10.1056/NEJMoa2601337. |
| [2] | D?rner T. Obexelimab and the promise of nondepleting B-cell therapy in IgG4-related disease[J/OL]. N Engl J Med (2026-06-02) [2026-07-19]. https://www.nejm.org/doi/full/10.1056/NEJMe2605617. |
| [3] | Kawa S, Okazaki K, Notohara K, et al. Autoimmune pancreatitis complicated with inflammatory bowel disease and comparative study of type 1 and type 2 autoimmune pancreatitis[J]. J Gastroenterol, 2015, 50(7): 805-815. |
| [4] | Lin W, Lu S, Chen H, et al. Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients[J]. Rheumatology (Oxford), 2015, 54(11): 1982-1990. |
| [5] | Stone JH, Khosroshahi A, Zhang W, et al. Inebilizumab for treatment of IgG4-related disease[J]. N Engl J Med, 2025, 392(12): 1168-1177. |
| [6] | Kacar M, Al-Hakim A, Savic S. Sequelae of B-cell depleting therapy: an immunologist’s perspective[J]. BioDrugs, 2025, 39(1): 103-130. |
| [7] | Cai S, Chen Y, Ye C, et al. Anti-BCMA CAR-T for the treatment of IgG4-related disease: clinical assessment and single-cell transcriptomic analysis[J]. Lancet Rheumatol, 2025, 7(12): e834-e836. |
| [8] | Keitel V, Kreissl MC, Goetze T, et al. CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement[J]. J Hepatol, 2026, 84(4): 829-836. |
| [9] | Hu J, Yu Y, Yang Y, et al. Effects of anti-CD19 CAR-T cells in a murine model of IgG4-related disease[J]. Arthritis Res Ther, 2026, 28(1): 47. |
/
| 〈 |
|
〉 |
